Two cancer immunotherapy drugs, nivolumab and Keytruda, proved remarkably effective against the blood cancer Hodgkin lymphoma in two small, separate studies. The studies add to growing evidence of the potential for enlisting the immune system in the fight against a wide range of tumors. Margaret Shipp, professor of medicine at the Dana Farber Cancer Institute, is a senior co-author of the nivolumab study.
